Bevacizumab: The need for controlled studies to move forward

Canadian Journal of Ophthalmology

Volumn 42, Issue 6, 2007, Pages 789-

  Buys, Yvonne M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

BLURRED VISION; CANCER IMMUNOTHERAPY; COLORECTAL CANCER; CORNEA ABRASION; CORNEA DISEASE; DRUG SAFETY; EDITORIAL; ENDOPHTHALMITIS; EYE DISCOMFORT; EYE DISEASE; EYE FOREIGN BODY SENSATION; EYELID IRRITATION; GLAUCOMA; HUMAN; INTRAOCULAR HEMORRHAGE; INTRAOCULAR PRESSURE; MEDICAL RESEARCH; NEOVASCULARIZATION (PATHOLOGY); PIGMENT EPITHELIUM TEAR; RETINA DETACHMENT; SIDE EFFECT; SUBCONJUNCTIVAL HEMORRHAGE; SUBRETINAL HEMORRHAGE; TREATMENT OUTCOME; UVEITIS; VITREOUS BODY DETACHMENT; VITRITIS;

EID: 38149061985     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.3129/I07-176     Document Type: Editorial

References (3)

1. Lynch SS, Cheng CM. Bevacizumab for neovascular ocular diseases. Ann Pharmacother 2007;41:614-25.
2. Hollands H, Wong J, Bruen R, Campbell RJ, Sharma S, Gale J. Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol 2007;42:807-11.
3. Kernt M, Neubauer AS, Kampik A. Intravitreal bevacizumab (Avastin) treatment is safe in terms of intraocular and blood pressure. Acta Ophthalmol Scand 2007;85:119-20.